Startup Scout 2 Mar 2018 This Spanish Biotech Is Developing Stem-Cell Targeted Leukemia Treatments This week, we’re in Barcelona, Spain, to visit Leukos Biotech, whose goal is to develop new treatments and diagnostic tools for Leukaemia. Mission: Founded in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute (IJC), Leukos Biotech has raised €3.5M in funding and has identified a new therapeutic target against leukemic stem cells in acute […] March 2, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 Novartis Takes Genmab’s Leukemia Drug Off the Market Genmab’s leukemia drug will be available around the world through compassionate use programs, while it will continue to be marketed as normal in the US. Blockbuster drug owner Genmab developed Arzerra for the treatment of chronic lymphocytic leukemia (CLL) but the drug will be taken off the market outside the US due to its low uptake. Novartis markets the drug and […] January 22, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Dec 2017 Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017 Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […] December 18, 2017 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment Data presented at ASH 2017 shows that Servier and Pfizer’s UCART19, an allogeneic CAR-T therapy originally developed by Cellectis, might struggle to outperform autologous CAR-T cells. CAR-T cell therapy has proved to be effective at treating cancer in patients for whom scarce hope was left. Yet pricing is still a big concern. Companies like Cellectis are trying […] December 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech ADC Therapeutics is one of our top biotechs of the year after it brought in a massive $200M (€170M) fundraising round. The company develops antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Results from two Phase I studies […] December 11, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors suitable for bone marrow transplant to treat blood cancer. From its Amsterdam headquarters, Kiadis Pharma is developing a technology that could solve one of the biggest problems of bone marrow transplantation: finding a donor match. Currently, a bone marrow transplant is […] December 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2017 Welcome to the Blockbuster Club, Genmab! Genmab has achieved $1B sales in the US of its blood cancer drug, Darzalex, setting a great example for other European biotechs to follow. Genmab has officially joined the elite of the biotech world by achieving $1B (€850M) in sales of its drug for multiple myeloma, Darzalex. The biotech will now receive milestone payments of $50M (€42M) […] November 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form of cancer that affects the cells responsible for protecting our body against infections. Unlike it’s done with cancer types that affect other blood cells, it’s […] November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’ Gilead’s CAR-T cell therapy Yescarta has been approved by the FDA, making it the first competitor for Novartis’ CAR-T Kymriah. Yescarta (axicabtagene ciloleucel, or axi-cel for short) has become the second CAR-T therapy to be approved in the US. The FDA has authorized its use to treat aggressive B-cell non-Hodgkin lymphoma in patients for whom at least two […] October 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2017 Roche Abandons Spanish Cancer Epigenetics Drug Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […] July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2017 UPDATE: The First Off-the-Shelf CAR-T Cancer Therapy has Entered the Clinic Update (28/06/2017): Cellectis has announced the first administration of UCART123 in its Phase I trial in Acute Myeloid Leukemia. Update (07/02/2017): the FDA has granted Cellectis IND approval to start clinical trials with UCART123. Original publication 04/01/2017 Cellectis is preparing to start the first clinical trial ever using an allogeneic CAR-T therapy that could reduce […] June 28, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 22 May 2017 Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former Chief Strategy Officer of Crucell, which was sold to J&J in 2011, is now […] May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email